scholarly journals Multiscale Stochastic Modeling Connects Cancer Drug Resistance Mechanisms to Population Survival Rates

2019 ◽  
Author(s):  
Xiaoqiang Sun
Keyword(s):  
Drug Resistance ◽  
Stochastic Modeling ◽  
Survival Rates ◽  
Resistance Mechanisms ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Population Survival

Investigation of cancer drug resistance mechanisms by phosphoproteomics

2020 ◽  
Vol 160 ◽  
pp. 105091 ◽  
Author(s):  
Joelle C. Boulos ◽  
Muhammad Rahama Yousof Idres ◽  
Thomas Efferth
Keyword(s):  
Drug Resistance ◽  
Resistance Mechanisms ◽  
Cancer Drug ◽  
Cancer Drug Resistance

scholarly journals Extracellular Vesicles: Emerging Modulators of Cancer Drug Resistance

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 749
Author(s):  
Fabrizio Fontana ◽  
Emanuela Carollo ◽  
Genevieve E. Melling ◽  
David R. F. Carter
Keyword(s):  
Drug Resistance ◽  
Extracellular Vesicles ◽  
Resistance Mechanisms ◽  
Cancer Drug ◽  
Diagnosis And Prognosis ◽  
Cancer Drug Resistance ◽  
Resistant Phenotype ◽  
Molecular Events ◽  
Therapeutic Outcomes ◽  
Tumor Drugs

Extracellular vesicles (EVs) have recently emerged as crucial modulators of cancer drug resistance. Indeed, it has been shown that they can directly sequester anti-tumor drugs, decreasing their effective concentration at target sites. Moreover, they facilitate the horizontal transfer of specific bioactive cargoes able to regulate proliferative, apoptotic, and stemness programs in recipient cells, potentially conferring a resistant phenotype to drug-sensitive cancer cells. Finally, EVs can mediate the communication between the tumor and both stromal and immune cells within the microenvironment, promoting treatment escape. In this context, clarifying the EV-driven resistance mechanisms might improve not only tumor diagnosis and prognosis but also therapeutic outcomes. Detailed cellular and molecular events occurring during the development of EV-mediated cancer drug resistance are described in this review article.

Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance

2020 ◽  
Vol 20 (9) ◽  
pp. 779-787
Author(s):  
Kajal Ghosal ◽  
Christian Agatemor ◽  
Richard I. Han ◽  
Amy T. Ku ◽  
Sabu Thomas ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Dna Repair ◽  
Fanconi Anemia ◽  
Cancer Drug ◽  
Drug Resistant ◽  
Cancer Drugs ◽  
Repair Pathway ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Cancerous Cells

Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one common obstacle to the success is the development of chemoresistance, which leads to failure of the previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance

2020 ◽  
Vol 16 (34) ◽  
pp. 2863-2878
Author(s):  
Yang Liu ◽  
Qian Du ◽  
Dan Sun ◽  
Ruiying Han ◽  
Mengmeng Teng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Digital Pcr ◽  
Circulating Tumor Dna ◽  
Resistance Mechanisms ◽  
Clinical Applications ◽  
Current Status ◽  
Cancer Drug ◽  
Genomic Alteration ◽  
Tumor Dna

Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Unfortunately, treatments often fail because of the development of drug resistance, the underlying mechanisms of which remain unclear. Circulating tumor DNA (ctDNA) is free DNA released into the blood by necrosis, apoptosis or direct secretion by tumor cells. In contrast to repeated, highly invasive tumor biopsies, ctDNA reflects all molecular alterations of tumors dynamically and captures both spatial and temporal tumor heterogeneity. Highly sensitive technologies, including personalized digital PCR and deep sequencing, make it possible to monitor response to therapies, predict drug resistance and tailor treatment regimens by identifying the genomic alteration profile of ctDNA, thereby achieving precision medicine. This review focuses on the current status of ctDNA biology, the technologies used to detect ctDNA and the potential clinical applications of identifying drug resistance mechanisms by detecting tumor-specific genomic alterations in breast cancer.

scholarly journals Recent Progress in Characterizing Long Noncoding RNAs in Cancer Drug Resistance

2019 ◽  
Vol 10 (26) ◽  
pp. 6693-6702 ◽  
Author(s):  
Wenyuan Zhao ◽  
Bin Shan ◽  
Dan He ◽  
Yuanda Cheng ◽  
Bin Li ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Recent Progress ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Cancer Drug ◽  
Cancer Drug Resistance

Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance

2021 ◽  
Author(s):  
Peng Xie ◽  
Yushu Wang ◽  
Dengshuai Wei ◽  
Lingpu Zhang ◽  
Bin Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Resistance ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Cancer Drug ◽  
Platinum Drugs ◽  
Effective Strategy ◽  
Platinum Drug ◽  
Cancer Drug Resistance ◽  
Platinum Drug Resistance

The mechanisms of chemoresistance and nanoparticle-based drug delivery systems for platinum drugs were detailed summarized in this review. The current combination therapy provided an effective strategy to overcome the platinum drug resistance.

Sign in / Sign up

Export Citation Format

Share Document